NCT07169617 2026-04-20Testing the SurVaxM Vaccine for Lung Cancer PreventionNational Cancer Institute (NCI)Phase 2 Not yet recruiting80 enrolled
NCT07537400 2026-04-17Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5Shaare Zedek Medical CenterPhase 2 Not yet recruiting10 enrolled